Popadic, Svetlana (24830928800)Svetlana (24830928800)PopadicLekic, Branislav (56092444000)Branislav (56092444000)LekicTanasilovic, Srdjan (24169980600)Srdjan (24169980600)TanasilovicBosic, Martina (56606207600)Martina (56606207600)BosicNikolic, Milos (56910382000)Milos (56910382000)Nikolic2025-06-122025-06-122020https://doi.org/10.1111/dth.13152https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075375829&doi=10.1111%2fdth.13152&partnerID=40&md5=90f2b99153e3125c1a62534ddf1fbf96https://remedy.med.bg.ac.rs/handle/123456789/5340We present a patient with a 33-year history of poikilodermatous mycosis fungoides (MF) who subsequently developed CD30-positive large cell transformation. After 6 years of conventional MF treatment, side effects of therapy and/or concomitant diseases prevented the previously applied treatment modalities. The CD30-directed antibody-cytotoxic drug conjugate (brentuximab vedotin) was introduced and followed by quick and excellent therapeutic response. © 2019 Wiley Periodicals, Inc.brentuximab vedotinCD30-positive large cell transformationmycosis fungoides